Skip to main content
NCBI home page
Environmental Health Perspectives logoLink to Environmental Health Perspectives
. 1995 Nov;103(Suppl 8):269–273. doi: 10.1289/ehp.95103s8269

Viruses and human cancers: challenges for preventive strategies.

G de The 1
PMCID: PMC1518983  PMID: 8741797

Abstract

Virus-associated human cancers provide unique opportunities for preventive strategies. The role of human papilloma viruses (HPV 16 and 18), hepatitis B virus (HBV), Epstein-Barr herpes virus (EBV), and retroviruses (human immunodeficiency virus [HIV] and human T-cell leukemia/lymphoma virus [HTLV]) in the development of common carcinomas and lymphomas represents a major cancer threat, particularly among individuals residing in developing countries, which account for 80% of the world's population. Even though these viruses are not the sole etiological agents of these cancers (as would be the case for infectious diseases), different approaches can be implemented to significantly decrease the incidence of virus-associated malignancies. The first approach is vaccination, which is available for HBV and possibly soon for EBV. The long delay between primary viral infection and development of associated tumors as well as the cost involved with administering vaccinations detracts from the feasibility of such an approach within developing countries. The second approach is to increase efforts to detect pre-cancerous lesions or early tumors using immunovirological means. This would allow early diagnosis and better treatment. The third strategy is linked to the existence of disease susceptibility genes, and suggests that counseling be provided for individuals carrying these genes to encourage them to modify their lifestyles and other conditions associated with increased cancer risks (predictive oncology). Specific recommendations include: a) increase international studies that explore the causes of the large variations in prevalence of common cancers throughout the world; b) conduct interdisciplinary studies involving laboratory investigation and social sciences, which may suggest hypotheses that may then be tested experimentally; and c) promote more preventive and health enhancement strategies in addition to curative and replacement therapies.

Full text

PDF
269

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burkitt D. P. Etiology of Burkitt's lymphoma--an alternative hypothesis to a vectored virus. J Natl Cancer Inst. 1969 Jan;42(1):19–28. [PubMed] [Google Scholar]
  2. Henle W., Henle G., Ho H. C., Burtin P., Cachin Y., Clifford P., de Schryver A., de-Thé G., Diehl V., Klein G. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst. 1970 Jan;44(1):225–231. [PubMed] [Google Scholar]
  3. Lu S. J., Day N. E., Degos L., Lepage V., Wang P. C., Chan S. H., Simons M., McKnight B., Easton D., Zeng Y. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region. Nature. 1990 Aug 2;346(6283):470–471. doi: 10.1038/346470a0. [DOI] [PubMed] [Google Scholar]
  4. Moss D. J., Burrows S. R., Castelino D. J., Kane R. G., Pope J. H., Rickinson A. B., Alpers M. P., Heywood P. F. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea. Int J Cancer. 1983 Jun 15;31(6):727–732. doi: 10.1002/ijc.2910310609. [DOI] [PubMed] [Google Scholar]
  5. Sixbey J. W., Yao Q. Y. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science. 1992 Mar 20;255(5051):1578–1580. doi: 10.1126/science.1312750. [DOI] [PubMed] [Google Scholar]
  6. Tuyns A. J., Péquignot G., Jensen O. M. Le cancer de l'oesophage en Ille-et-Vilaine en fonction des niveaux de consommation d'alcool et de tabac. Des risques qui se multiplient. Bull Cancer. 1977;64(1):45–60. [PubMed] [Google Scholar]
  7. Zeng Y., Liu Y., Liu C. R., Chen S. W., Wei J. E., Zhu J. S., Zai H. J. [Application of immunoenzymic method and immunoautoradiographic method for the mass survey of nasopharyngeal carcinoma (author's transl)]. Zhonghua Zhong Liu Za Zhi. 1979;1(1):2–7. [PubMed] [Google Scholar]
  8. Zeng Y., Ohshima H., Bouvier G., Roy P., Zhong J., Li B., Brouet I., de Thé G., Bartsch H. Urinary excretion of nitrosamino acids and nitrate by inhabitants of high- and low-risk areas for nasopharyngeal carcinoma in southern China. Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):195–200. [PubMed] [Google Scholar]
  9. de-Thé G., Geser A., Day N. E., Tukei P. M., Williams E. H., Beri D. P., Smith P. G., Dean A. G., Bronkamm G. W., Feorino P. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature. 1978 Aug 24;274(5673):756–761. doi: 10.1038/274756a0. [DOI] [PubMed] [Google Scholar]
  10. de-Vathaire F., Sancho-Garnier H., de-Thé H., Pieddeloup C., Schwaab G., Ho J. H., Ellouz R., Micheau C., Cammoun M., Cachin Y. Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC): a multicenter follow-up study. Int J Cancer. 1988 Aug 15;42(2):176–181. doi: 10.1002/ijc.2910420206. [DOI] [PubMed] [Google Scholar]
  11. zur Hausen H., Schulte-Holthausen H., Klein G., Henle W., Henle G., Clifford P., Santesson L. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970 Dec 12;228(5276):1056–1058. doi: 10.1038/2281056a0. [DOI] [PubMed] [Google Scholar]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Sciences

RESOURCES